<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02918253</url>
  </required_header>
  <id_info>
    <org_study_id>16-5490</org_study_id>
    <nct_id>NCT02918253</nct_id>
  </id_info>
  <brief_title>HDR Focal: Feasibility Study</brief_title>
  <official_title>HDR Monotherapy for Prostate Cancer: A Feasibility Study of Focal Radiotherapy Yields</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brachytherapy as a monotherapy treatment is highly effective for localized prostate cancer,&#xD;
      traditionally being delivered to the whole prostate gland. Lately, low dose rate (LDR)&#xD;
      brachytherapy has been increasingly replaced by high dose rate (HDR) brachytherapy treatment&#xD;
      schemes. While brachytherapy's oncologic outcomes are excellent, it is not without incidence&#xD;
      adverse effects including urinary, rectal, and sexual toxicities that affect the patient's&#xD;
      quality of life.&#xD;
&#xD;
      This study will incorporate HDR monotherapy treatment option for early stages and favourable&#xD;
      risk prostate cancer.&#xD;
&#xD;
      Additionally, we aim to evaluate the role of focal HDR brachytherapy for well-defined disease&#xD;
      based on multiparametric MRI (mpMRI). This approach may offer an option of reducing the&#xD;
      treatment toxicities while maintaining oncologic outcomes when compared with whole-gland&#xD;
      therapy. Advantages in quality of life could be exhibited in the form of reduced urinary&#xD;
      discomfort and incontinence, rectal symptoms, and improved erectile and prostatic gland&#xD;
      function. This study would be particularly relevant in the current era of earlier localized&#xD;
      prostate cancer detection, where newer imaging modalities (e.g. mpMRI) become a routine&#xD;
      component of patient care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2016</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients achieving biochemical control</measure>
    <time_frame>2 yrs</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Tumour visible on MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Targeted focal HDR Brachytherapy to dominant lesion +/- whole-gland elective dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No tumour visible on MRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Whole-gland HDR Brachytherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>targeted focal HDR brachytherapy</intervention_name>
    <arm_group_label>Tumour visible on MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Whole-gland HDR Brachytherapy</intervention_name>
    <description>Control/Standard of Care</description>
    <arm_group_label>No tumour visible on MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  ECOG performance status 0 - 2&#xD;
&#xD;
          -  Histological evidence of prostate adenocarcinoma&#xD;
&#xD;
          -  Low- and favorable intermediate-risk prostate cancer&#xD;
&#xD;
          -  Informed consent: All patients must sign a document of informed consent indicating&#xD;
             their understanding of the investigational nature and risks of the study before any&#xD;
             protocol related studies are performed&#xD;
&#xD;
          -  No contraindications to MRI:&#xD;
&#xD;
          -  Absent or unifocal intraprostatic disease (&lt;2 separate/distinct lesions), on&#xD;
             multiparametric MRI&#xD;
&#xD;
          -  Prostate gland size &lt;80cc&#xD;
&#xD;
          -  Baseline IPSS &lt;18&#xD;
&#xD;
          -  No TRUP within the past 6 months, nor large TURP defect&#xD;
&#xD;
          -  Absence of radiological evidence of regional or distant metastases (optional&#xD;
             evaluation, at physician discretion)&#xD;
&#xD;
          -  No previous pelvic and/or prostate EBRT and/or brachytherapy&#xD;
&#xD;
          -  No contraindications to general anesthesia, or spinal/epidural anesthesia&#xD;
&#xD;
          -  Absence of bleeding diathesis and/or anti-coagulative therapy that cannot be&#xD;
             temporarily ceased during brachytherapy&#xD;
&#xD;
          -  No contraindications to endorectal coil, surgically absent rectum, severe hemorrhoids&#xD;
             or colorectal surgery&#xD;
&#xD;
          -  Negative past medical history of Ulcerative Colitis, Crohn's Disease, Ataxia&#xD;
             Telangiectasia, or SLE&#xD;
&#xD;
          -  Absence of latex allergy&#xD;
&#xD;
          -  No other medical conditions deemed by the PI to make patient ineligible for prostate&#xD;
             HDR brachytherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alejandro Berlin, MD</last_name>
    <email>alejandro.berlin@rmp.uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alejandro Berlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2016</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High dose-rate brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

